Answers are grounded in this paper and cite their sources.
:Health Technology Assessment (HTA) is a comprehensive evaluation process that systematically examines health technologies, such as medications, medical devices, and prevention methods. HTA framework considers various factors, including medical, economic, social, and ethical aspects. The primary goal of HTA is to provide evidence-based information to national health authorities to aid in decision-making regarding reimbursement and pricing, in the context of other available therapy options in the country or region. Although specific countries may have differing focuses and requirements for HTA, the fundamental principles remain mostly consistent. This will require that statisticians, who have so far had limited involvement in HTA requirements, become familiar with the evaluation process and its components. To address this general knowledge gap, the American Statistical Association (ASA) Biopharmaceutical Section (BIOP) Health Technology Assessment (HTA) Scientific Working Group (SWG) has devoted significant effort to assess the HTA landscape in major markets worldwide. Our targeted audience comprises statisticians working within the clinical development space who may not be familiar with the connection and specifics of HTA needs. This landscape paper, authored by the SWG, aims to achieve several objectives that include introducing the conceptual framework of HTA evaluations, reviewing key HTA guidance documents from major markets, discussing the diverse evidence needs of major health authorities, and highlighting the statistical challenges and opportunities in this field.
No takes yet. Share an insight, caveat, or question.
Jen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: